CN112168814B - Application of fusidic acid A-ring amino thiazole ring derivative - Google Patents

Application of fusidic acid A-ring amino thiazole ring derivative Download PDF

Info

Publication number
CN112168814B
CN112168814B CN202011177190.6A CN202011177190A CN112168814B CN 112168814 B CN112168814 B CN 112168814B CN 202011177190 A CN202011177190 A CN 202011177190A CN 112168814 B CN112168814 B CN 112168814B
Authority
CN
China
Prior art keywords
alpha
beta
fusidic acid
hydroxy
aminothiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011177190.6A
Other languages
Chinese (zh)
Other versions
CN112168814A (en
Inventor
毕毅
王洪波
吉文涛
魏颖杰
钟丽娟
刘妍杰
龙俊俊
李小鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yantai University
Original Assignee
Yantai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yantai University filed Critical Yantai University
Priority to CN202011177190.6A priority Critical patent/CN112168814B/en
Publication of CN112168814A publication Critical patent/CN112168814A/en
Application granted granted Critical
Publication of CN112168814B publication Critical patent/CN112168814B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0073—Sulfur-containing hetero ring
    • C07J71/0094—Sulfur-containing hetero ring containing sulfur and nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the field of organic synthesis and pharmaceutical chemistry, in particular to a new application of fusidic acid A-ring amino thiazole ring derivatives with novel structures in preparing tumor drug resistance reversal agents. Fusidic acid is an antibacterial drug on the market, and has no tumor resistance reversion activity, and the fusidic acid derivative with the general formula I enables the sensitivity of tumor resistance cells KBV with drug resistance to paclitaxel to be obviously improved, so that paclitaxel can still generate good antitumor activity to the cells with very low concentration.

Description

Application of fusidic acid A-ring amino thiazole ring derivative
Technical Field
The invention relates to the field of organic synthesis and pharmaceutical chemistry, in particular to a new application of fusidic acid A-ring amino thiazole ring derivatives with novel structures in preparing tumor drug resistance reversal agents.
Technical Field
Malignant tumors are a serious threat to human health, and chemotherapy is currently one of the major methods for treating malignant tumors. Statistically, over 960 ten thousand tumor patients died in 2018, and studies have shown that multidrug resistance (MDR) of tumor cells to chemotherapeutic drugs is one of the major causes of chemotherapy failure. The natural products have the characteristic of various structures and become important sources for finding medicines or good lead compounds for treating serious diseases. The search and development of novel compounds with novel structure, low toxicity, safety and high MDR reversal activity from natural products is the hot content of research of tumor therapeutics and pharmacology.
Fusidic Acid (FA), a narrow spectrum highly potent antibiotic isolated from the fungus fusarium coccineum, is used in the treatment of skin infections, osteoarticular infections, burn infections, etc. caused by staphylococcus aureus and several other gram-positive bacteria. Fusidic acid has been extensively studied since its introduction in 1962, but has primarily focused on its antibacterial aspects.
Disclosure of Invention
The invention aims to provide a fusidic acid derivative with tumor drug resistance reversion activity and a novel structure and a preparation method thereof, and simultaneously provides a new application of the derivative in the field of tumor drug resistance reversion, which has important significance for developing a novel tumor drug resistance reversion agent.
The invention is realized by the following technical scheme:
the application of fusidic acid A-ring amino thiazole ring derivatives shown in a general formula I and pharmaceutically acceptable salts thereof in preparing tumor drug resistance reversal agents and pharmaceutically acceptable carriers,
Figure BDA0002749044380000011
wherein:
general formula I: r1Represents hydroxy, oxo;
R2represents OR3、
Figure BDA0002749044380000021
R3Represents H, halogen substituted or unsubstituted benzyl;
x represents C, N;
y represents F, Cl or Br.
Preferably, the A-ring aminothiazole ring derivatives of fusidic acid shown in the general formula I and pharmaceutically acceptable salts thereof,
wherein, the general formula I: r1Represents hydroxy, oxo;
R2represents OR3、
Figure BDA0002749044380000022
R3Represents H, benzyl;
x represents C, N;
y represents Cl.
Preferably, the A-ring aminothiazole ring derivatives of fusidic acid shown in the general formula I and pharmaceutically acceptable salts thereof,
wherein, the general formula I:
16 β -acetoxy-11 α -hydroxy-4 α,8 α,14 β -trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 α,10 β -cholest- (17Z) -17(20), benzyl 24-diene-21-oate;
16 beta-acetoxy-11 alpha-hydroxy-4 alpha, 8 alpha, 14 beta-trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 alpha, 10 beta-cholest- (17Z) -17(20), 24-diene-21-oic acid (7-azabenzotriazole-1) ester;
16 beta-acetoxyl-11 alpha-hydroxy-4 alpha, 8 alpha, 14 beta-trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 alpha, 10 beta-cholest- (17Z) -17(20), 24-diene-21-acid (6-chloro-1H-benzotriazole-1) ester;
16 β -acetoxy-11 α -hydroxy-4 α,8 α,14 β -trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 α,10 β -cholest- (17Z) -17(20), 24-diene-21-oic acid (1,2, 3-benzotriazin-4 (3H) -one-3) ester;
16 beta-acetoxyl group-11 alpha-hydroxy-4 alpha, 8 alpha, 14 beta-trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 alpha, 10 beta-cholest- (17Z) -17(20), 24-diene-21-acid (1H-benzotriazole-1) ester.
A process for the preparation of a Cycloaminothiazolo ring derivative of fusidic acid of general formula I and pharmaceutically acceptable salts thereof, when R is1When the hydroxyl is adopted, the preparation steps comprise:
a. oxidizing 3-hydroxy group with pyridine chlorochromate;
b. under the alkaline condition and the action of a catalyst, reacting the product obtained in the step a with alcohol or benzyl bromide;
c.b reacting the product with pyridinium tribromide and thiourea.
When R is1When the group is oxo, the preparation steps comprise:
a. oxidizing 3, 11-hydroxy with pyridine chlorochromate;
b. under the alkaline condition and the action of a catalyst, reacting the product obtained in the step a with alcohol or benzyl bromide;
c.b reacting the product with pyridinium tribromide and thiourea.
The invention relates to the use of fusidic acid derivatives of general formula I and pharmaceutically acceptable salts thereof for the preparation of tumour resistance-reversing agents and/or pharmaceutically acceptable carriers for the treatment of animals, preferably human diseases or conditions.
The effective amount of the tumor drug resistance reversal agent prepared from the fusidic acid derivative of the general formula I and the medically acceptable salt thereof is used together with clinical antitumor drugs for treating diseases or symptoms such as gastric cancer, lung cancer, cervical cancer, breast cancer or colon cancer. Preferably, the clinical antitumor drug is paclitaxel.
Fusidic acid is an antibacterial drug on the market, and has no tumor resistance reversion activity, and the fusidic acid derivative with the general formula I enables the sensitivity of tumor resistance cells KBV with drug resistance to paclitaxel to be obviously improved, so that paclitaxel can still generate good antitumor activity to the cells with very low concentration, and the pharmacological test of the specific implementation mode part can be seen.
Detailed Description
1. The present invention will be described in further detail below by way of examples, but the present invention is not limited to only the following examples.
Example 1
16 β -acetoxy-11 α -hydroxy-4 α,8 α,14 β -trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 α,10 β -cholest- (17Z) -17(20), 24-diene-21-oic acid benzyl ester
500mL of eggplant-shaped bottle was taken, fusidic acid (10.0g, 19.4mmol) was dissolved in anhydrous dichloromethane (200mL), freshly prepared PCC (5.4g, 25.2mmol) was added, and the reaction was stirred at room temperature for 5 hours. After the reaction is finished, dichloromethane is diluted, water washing is carried out, saturated salt water washing is carried out, anhydrous sodium sulfate is dried, filtration and concentration are carried out, and silica gel column chromatography (V)Chloroform:VMethanol100:1) to give X1(3.2g, 32.5%) as a white solid.
A250 mL eggplant-shaped bottle was taken, X1(2.5g, 4.9mmol) was dissolved in DMF (100mL), potassium carbonate (1.4g, 9.7mmol) and benzyl bromide (0.9mL, 7.3mmol) were added, and the reaction was stirred at 50 ℃ for 6 hours. After the reaction is finished, diluting with ethyl acetate, washing with water, washing with saturated salt water, drying with anhydrous sodium sulfate, filtering, concentrating, and performing silica gel column chromatography (V)Chloroform:VMethanol100:1) to give X2(2.2g, 74.5%) as a white solid.
100mL of eggplant-shaped bottle was taken, and X2(1.0g, 1.7mmol) was dissolved in chloroformTo an alkane (40mL) was added pyridinium tribromide (0.8g, 2.4mmol), and the reaction was stirred at room temperature for 8 hours. After the reaction is finished, the solvent is evaporated, the ethyl acetate is diluted, the mixture is washed by water, the saturated salt solution is washed by water, the anhydrous sodium sulfate is dried, the mixture is filtered, the concentration is carried out, and the silica gel column chromatography (V) is carried outChloroform:VMethanol100:1) to give X3(0.6g, 52.5%) as a white solid.
A50 mL eggplant-shaped bottle was taken, X3(100mg, 146. mu. mol) was dissolved in absolute ethanol (30mL), thiourea (54.5mg, 0.7mmol) was added, and the reaction was refluxed at 80 ℃ for 6 hours. After the reaction is finished, the solvent is evaporated and silica gel column chromatography is carried out (V)Chloroform:VMethanol90:1) to give a pale yellow solid (60.5mg, 62.8%).1H-NMR(CDCl3,400MHz)δ:7.45-7.28(m,5H,5×Ar-H),5.93(d,J＝8.40Hz,1H,16-H),5.24(d,J＝12.20Hz,1H,CHAr),5.09(t,J＝7.20Hz,1H,24-H),4.96(d,J＝12.20Hz,1H,CHAr),4.40(s,1H,11-H),3.70-3.68(m,1H,4-H),3.49-3.47(m,1H,1-H),3.25-3.21(m,1H,1-H),3.04(d,J＝11.50Hz,1H,13-H),2.49-2.42(m,2H,2×22-H),2.37-2.28(m,1H,12-H),2.26-2.00(m,4H,15-H,2×23-H and 5-H),1.95(s,3H,OCOCH3),1.93-1.76(m,2H,12-H and 7-H),1.66(s,3H,27-CH3),1.65-1.57(m,2H,6-H and 9-H),1.55(s,3H,26-CH3),1.31(s,3H,30-CH3),1.36-1.27(m,3H,15-H,6-H and 7-H),1.01(s,3H,19-CH3),0.97(s,3H,18-CH3),0.89(s 3H,28-CH3).
Example 2
16 beta-acetoxy-11 alpha-hydroxy-4 alpha, 8 alpha, 14 beta-trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 alpha, 10 beta-cholest- (17Z) -17(20), 24-diene-21-oic acid (7-azabenzotriazole-1) ester;
synthetic method reference example 1 gave a pale yellow solid (66.8mg, 69.0%).1H-NMR(CDCl3,400MHz)δ:8.53-8.50(m,1H,Pyr-H),8.25-8.20(m,1H,Pyr-H),7.30-7.27(m,1H,Pyr-H),5.85(d,J＝8.40Hz,1H,16-H),5.09(t,J＝7.20Hz,1H,24-H),4.38(s,1H,11-H),4.16-4.12(m,1H,4-H),4.00-3.96(m,1H,1-H),3.23-3.18(m,1H,1-H),3.03(d,J＝11.50Hz,1H,13-H),2.48-2.45(m,2H,2×22-H),2.37-2.28(m,1H,12-H),2.26-2.00(m,4H,15-H,2×23-H and 5-H),1.95(s,3H,OCOCH3),1.93-1.85(m,2H,12-H and 7-H),1.66(s,3H,27-CH3),1.63-1.60(m,2H,6-H and 9-H),1.58(s,3H,26-CH3),1.27(s,3H,30-CH3),1.23(s,3H,19-CH3),0.92(s,3H,18-CH3),0.89(s,3H,28-CH3).
Example 3
16 beta-acetoxyl-11 alpha-hydroxy-4 alpha, 8 alpha, 14 beta-trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 alpha, 10 beta-cholest- (17Z) -17(20), 24-diene-21-acid (6-chloro-1H-benzotriazole-1) ester;
synthetic method reference example 1 gave a pale yellow solid (62.9mg, 64.9%).1H-NMR(CDCl3,400MHz)δ:7.72-7.69(m,1H,Ar-H),7.60(s,1H,Ar-H),7.21(m,1H,Ar-H),5.86(d,J＝8.40Hz,1H,16-H),5.07(t,J＝7.20Hz,1H,24-H),4.33(s,1H,11-H),4.21-4.18(m,1H,4-H),4.01-3.98(m,1H,1-H),3.21-3.16(m,1H,1-H),3.02(d,J＝11.50Hz,1H,13-H),2.44-2.38(m,2H,2×22-H),2.37-2.28(m,1H,12-H),2.26-2.00(m,4H,15-H,2×23-H and 5-H),1.96(s,3H,OCOCH3),1.93-1.76(m,2H,12-H and 7-H),1.66(s,3H,27-CH3),1.65-1.59(m,2H,6-H and 9-H),1.58(s,3H,26-CH3),1.28(s,3H,30-CH3),1.24(s,3H,19-CH3),0.91(s,3H,18-CH3),0.87(s,3H,28-CH3).
Example 4
16 β -acetoxy-11 α -hydroxy-4 α,8 α,14 β -trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 α,10 β -cholest- (17Z) -17(20), 24-diene-21-oic acid (1,2, 3-benzotriazin-4 (3H) -one-3) ester;
synthetic method reference example 1 gave a pale yellow solid (60.3mg, 62.2%).1H-NMR(CDCl3,400MHz)δ:8.36-8.34(m,1H,Ar-H),8.21-8.19(m,1H,Ar-H),8.00-7.98(m,1H,Ar-H),7.84-7.80(m,1H,Ar-H),5.96(d,J＝8.40Hz,1H,16-H),5.19(t,J＝7.20Hz,1H,24-H),4.40(s,1H,11-H),3.42-3.40(m,1H,4-H),3.25-3.15(m,2H,2×1-H),3.14(d,J＝11.50Hz,1H,13-H),2.44-2.38(m,2H,2×22-H),2.37-2.28(m,1H,12-H),2.26-2.20(m,4H,15-H,2×23-H and 5-H),2.08(s,3H,OCOCH3),1.93-1.76(m,2H,12-H and 7-H),1.66(s,3H,27-CH3),1.65-1.59(m,2H,6-H and 9-H),1.42(s,3H,26-CH3),1.27(s,3H,30-CH3),1.24(s,3H,19-CH3),1.01(s,3H,18-CH3),0.95(s,3H,28-CH3).
Example 5
16 beta-acetoxyl-11 alpha-hydroxy-4 alpha, 8 alpha, 14 beta-trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 alpha, 10 beta-cholest- (17Z) -17(20), 24-diene-21-oic acid (1H-benzotriazole-1) ester
Synthetic method reference example 1 gave a pale yellow solid (68.7mg, 71.0%).1H-NMR(CDCl3,400MHz)δ:7.77-7.75(m,1H,Ar-H),7.67-7.66(m,1H,Ar-H),7.36-7.33(m,2H,Ar-H),5.86(d,J＝8.40Hz,1H,16-H),5.08(t,J＝7.20Hz,1H,24-H),4.35(s,1H,11-H),3.76-3.72(m,1H,4-H),3.50-3.40(m,1H,1-H),3.36-3.32(m,1H,1-H),3.12-3.10(m,1H,13-H),2.49-2.42(m,2H,2×22-H),2.37-2.28(m,1H,12-H),2.26-2.00(m,4H,15-H,2×23-H and 5-H),1.95(s,3H,OCOCH3),1.93-1.76(m,2H,12-H and 7-H),1.64(s,3H,27-CH3),1.65-1.59(m,2H,6-H and 9-H),1.57(s,3H,26-CH3),1.23(s,3H,30-CH3),1.11(s,3H,19-CH3),1.05(s,3H,18-CH3),0.90(s,3H,28-CH3).
2. The following are the results of pharmacological experiments with some of the compounds of the invention.
(1) The experimental method comprises the following steps: examples 1-5 detection of the survival Rate of the antitumor drug paclitaxel in KBV resistant Strain cells
Cell plating: taking KBV drug-resistant strain cells with good growth state in logarithmic phase, adding culture medium after trypsinization, and gently blowing and beating to obtain single cell suspension. After cell counting, the cell concentration was diluted to 3-4X 10 with the medium4cells/mL were seeded in a 96-well cell plate culture plate at a volume of 100. mu.L/well, and were left to stand in a carbon dioxide incubator.
Cell administration: after 24h of cell plating, 10. mu.M of each of the different compounds was added in combination with 100nM of Paclitaxel and corresponding solvent control cultures. Each set of 3 parallel wells. And (4) after the medicine is added, placing the 96-well plate in an incubator, and performing static culture for 72 hours.
MTT detection: after the cells were cultured for 72 hours after administration of the corresponding drugs, the cell viability was examined.
(2) The experimental results are as follows:
examples 1-5 cell viability when administered alone and in combination is shown in Table 1.
TABLE 1 cell viability of examples 1-5 when administered alone and in combination
Figure BDA0002749044380000061
Examples 1-5 survival assay of antitumor drug paclitaxel in KBV resistant strain cells:
the survival rate evaluation result of KBV drug-resistant strain cells of the derivative shows that fusidic acid has no tumor drug resistance reversal activity per se, and examples 1-5 have better tumor drug resistance reversal activity, wherein the activity is best in example 3, and the effect is better than the activity of a common antitumor drug Verapamil (Verapamil) 40.37 +/-2.62%. The reason for the analysis is that aminothiazole ring as heterocyclic amine is introduced into a structure to easily form a plurality of effects such as hydrogen bond, hydrophobic effect, coordination bond and the like with a target spot, so that the fusidic acid derivative with a novel structure is prepared, and meanwhile, the novel application of the derivative in the field of tumor drug resistance reversal is provided, and the method has important significance for developing a novel tumor drug resistance reversal agent.
Although the preferred embodiments of the present invention have been described in detail, the present invention is not limited to the details of the embodiments, and various equivalent modifications can be made within the technical spirit of the present invention, and the scope of the present invention is also within the scope of the present invention. It should be noted that the various features described in the above embodiments may be combined in any suitable manner without departing from the scope of the invention. The invention is not described in detail in order to avoid unnecessary repetition. In addition, any combination of the various embodiments of the present invention is also possible, and the same should be considered as the disclosure of the present invention as long as it does not depart from the spirit of the present invention.

Claims (1)

1. The application of fusidic acid derivative and pharmaceutically acceptable salt thereof in preparing a drug resistance reversal agent of tumor drug resistant cell KBV resistant to paclitaxel is characterized in that the fusidic acid derivative is as follows:
16 β -acetoxy-11 α -hydroxy-4 α,8 α,14 β -trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 α,10 β -cholest- (17Z) -17(20), benzyl 24-diene-21-oate;
16 beta-acetoxy-11 alpha-hydroxy-4 alpha, 8 alpha, 14 beta-trimethyl-2, 3-and [2,3-b ] aminothiazole-18-nor-5 alpha, 10 beta-cholest- (17Z) -17(20), 24-diene-21-oic acid (7-azabenzotriazole-1) ester;
16 beta-acetoxyl-11 alpha-hydroxy-4 alpha, 8 alpha, 14 beta-trimethyl-2, 3-and [2,3-b ]]Aminothiazole-18-nor-5 alpha, 10 beta-cholest- (17Z) -17(20), 24-diene-21-oic acid (6-chloro-1)H-benzotriazole-1) esters;
16 beta-acetoxyl-11 alpha-hydroxy-4 alpha, 8 alpha, 14 beta-trimethyl-2, 3-and [2,3-b ]]Aminothiazole-18-nor-5 alpha, 10 beta-cholest- (17Z) -17(20), 24-diene-21-oic acid (1,2, 3-benzotriazine-4 (3)H) -keto-3) esters;
16 beta-acetoxyl-11 alpha-hydroxy-4 alpha, 8 alpha, 14 beta-trimethyl-2, 3-and [2,3-b ]]Aminothiazole-18-nor-5 alpha, 10 beta-cholest- (17Z) -17(20), 24-diene-21-oic acid (1)HBenzotriazole-1) esters.
CN202011177190.6A 2020-10-28 2020-10-28 Application of fusidic acid A-ring amino thiazole ring derivative Active CN112168814B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011177190.6A CN112168814B (en) 2020-10-28 2020-10-28 Application of fusidic acid A-ring amino thiazole ring derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011177190.6A CN112168814B (en) 2020-10-28 2020-10-28 Application of fusidic acid A-ring amino thiazole ring derivative

Publications (2)

Publication Number Publication Date
CN112168814A CN112168814A (en) 2021-01-05
CN112168814B true CN112168814B (en) 2022-01-11

Family

ID=73916559

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011177190.6A Active CN112168814B (en) 2020-10-28 2020-10-28 Application of fusidic acid A-ring amino thiazole ring derivative

Country Status (1)

Country Link
CN (1) CN112168814B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors
WO2019135715A1 (en) * 2018-01-05 2019-07-11 Nanyang Technological University Lipid-polymer hybrid nanoparticles
CN108904509B (en) * 2018-09-21 2021-03-23 烟台大学 Application of fusidic acid derivatives in preparation of antitumor drugs
CN109662969B (en) * 2018-11-21 2021-05-25 烟台大学 Application of fusidic acid derivatives in tumor drug resistance reversal activity
CN109608512B (en) * 2018-11-21 2021-05-14 烟台大学 Fusidic acid derivatives with tumor resistance reversal activity
CN111471080B (en) * 2020-05-26 2022-04-12 烟台大学 ocotillol type ginsengenin A-ring amino thiazole ring derivative and preparation method thereof

Also Published As

Publication number Publication date
CN112168814A (en) 2021-01-05

Similar Documents

Publication Publication Date Title
Zhu et al. Design and stereoselective synthesis of novel isosteviol-fused pyrazolines and pyrazoles as potential anticancer agents
CN108794564B (en) Hederagenin A-ring-and-pyrazine derivative as well as preparation method and application thereof
CN110483608B (en) Arenobufagin derivative, preparation method thereof, composition containing arenobufagin derivative and application of arenobufagin derivative
CN106749494A (en) α hederagenin derivatives with tumor drug resistance reversal activity and its production and use
CN105085383B (en) 5 methyl 2 (1H) Pyridione derivatives and its production and use
WO2013107428A1 (en) 7-substituted hanfangichin b derivative, and preparation method and use thereof
CN112168814B (en) Application of fusidic acid A-ring amino thiazole ring derivative
CN110964078A (en) Hederagenin compound H-X with anti-lung cancer effect and preparation method and application thereof
CN110028546A (en) The pentamethylene and more hydrogen phenanthrene framework compounds and application thereof of antitumor action are played with regulation factor VIII activity level
CN112159455B (en) Fusidic acid A-ring amino thiazole ring derivative and preparation method thereof
CN111471080A (en) ocotillol type ginsengenin A-ring amino thiazole ring derivative and preparation method thereof
CN108440550B (en) A kind of isochroman diindyl derivative and preparation method thereof
CN104530081B (en) The azacyclo-derivant of rapamycin and purposes
CN111303027A (en) Fluroxacin acrylketone derivative and preparation method and application thereof
CN107513089B (en) Novel cytidine derivative dimer and application thereof
CN110156816B (en) Tetrahydropyrazolopiperazine compound and preparation method and application thereof
EP4314004A1 (en) Carboxy substituted glucocorticoid receptor agonists
CN104530072B (en) Bromo norcantharidin mono-acid methyl ester and its synthetic method and application
CN112824397B (en) Lomefloxacin propenone derivative and preparation method and application thereof
CN106946974B (en) Ursolic amide derivative containing pyrazole heterocycle and synthesis and application thereof
WO2013079017A1 (en) 2-alkyl-or-aryl-substituted tanshinone derivatives, and preparation method and application thereof
CN114191439B (en) Application of C-23-position nitrogen-containing heterocyclic derivative of A-cycloisoxazole-ring hederagenin
CN110804084B (en) Quaternary phosphonium salt diosgenin derivative and synthesis method and application thereof
CN114213501B (en) C-23 nitrogen-containing heterocyclic derivative of cycloisoxazole ring hederagenin and preparation method thereof
CN113651867B (en) Sulfonamide 18 beta-glycyrrhetinic acid derivative and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant